Literature DB >> 11221851

Expression of adrenomedullin and peptide amidation activity in human prostate cancer and in human prostate cancer cell lines.

P Rocchi1, F Boudouresque, A J Zamora, X Muracciole, E Lechevallier, P M Martin, L Ouafik.   

Abstract

After therapeutic hormone deprivation, prostate cancer (CaP) cells often develop androgen-independent growth through not-well-defined mechanisms. The presence of neuroendocrine (NE) cells is often greater in prostate carcinoma than in normal prostate, and the frequency of NE cells correlates with tumor malignancy, loss of androgen sensitivity, increase of autocrine-paracrine activity, and poor prognosis. In some CaPs, neuropeptides have been previously implicated as growth factors. Peptidylglycine alpha-amidating monooxygenase (PAM) is the enzyme producing alpha-amidated bioactive peptides from their inactive glycine-extended precursors. In the present work, we demonstrate that androgen-independent PC-3 and DU145 cell lines, derived from human CaP, express PAM in vitro and in xenografts implanted in athymic nude mice, indicating that they are able to produce alpha-amidated peptides. Contrarily, barely detectable levels of PAM were found in the androgen-sensitive LNCaP cell line. We also show that whereas PC-3 and DU145 cells produce and secrete adrenomedullin (AM), a multifunctional amidated peptide, no expression was found in LNCaP cells. We further demonstrate that AM acts as a growth factor for DU145 cells, which suggests the existence of an autocrine loop mechanism that could potentially drive neoplastic growth. PAM mRNA levels were found to be 3-fold higher in prostate adenocarcinomas compared with that of human benign prostate hyperplasia (BPH) as demonstrated by real-time quantitative reverse transcription-PCR. The analysis of AM message expression in BPH and CaP (Gleason's score, 6-9) shows a clear distinction between benign and CaP. The expression was detected only in adenocarcinomas tissues with a marked increase in samples with a high Gleason's score. Immunocytochemically, AM was localized in the carcinomatous epithelial compartment. NE phenotype, assessed after the immunocytochemical localization of neuron-specific enolase (NSE), was found in both the epithelial and the stromal compartments of cancers; in BPH, only some spare basal cells were NSE-labeled. Cancer progression could be accelerated by peptides secreted by a population of cells capable of inducing androgen-independent tumoral growth via autocrine-paracrine mechanisms.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11221851

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  22 in total

1.  Prediction of protein amidation sites by feature selection and analysis.

Authors:  Weiren Cui; Shen Niu; Lulu Zheng; Lele Hu; Tao Huang; Lei Gu; Kaiyan Feng; Ning Zhang; Yudong Cai; Yixue Li
Journal:  Mol Genet Genomics       Date:  2013-06-21       Impact factor: 3.291

Review 2.  Endo/exo-proteolysis in neoplastic progression and metastasis.

Authors:  Abdel-Majid Khatib; Daniel Bassi; Geraldine Siegfried; Andres J P Klein-Szanto; L'Houcine Ouafik
Journal:  J Mol Med (Berl)       Date:  2005-08-26       Impact factor: 4.599

3.  PTEN inhibits adrenomedullin expression and function in brain tumor cells.

Authors:  Simone A Betchen; Sergei Musatov; Jill Roberts; John Pena; Michael G Kaplitt
Journal:  J Neurooncol       Date:  2006-07-05       Impact factor: 4.130

4.  Inactivation of peptidylglycine α-hydroxylating monooxygenase by cinnamic acid analogs.

Authors:  Neil R McIntyre; Edward W Lowe; Matthew R Battistini; James W Leahy; David J Merkler
Journal:  J Enzyme Inhib Med Chem       Date:  2015-05-29       Impact factor: 5.051

5.  Adrenomedullin is a cross-talk molecule that regulates tumor and mast cell function during human carcinogenesis.

Authors:  Enrique Zudaire; Alfredo Martínez; Mercedes Garayoa; Rubén Pío; Gurmeet Kaur; Michael R Woolhiser; Dean D Metcalfe; William A Hook; Reuben P Siraganian; Theresa A Guise; John M Chirgwin; Frank Cuttitta
Journal:  Am J Pathol       Date:  2006-01       Impact factor: 4.307

6.  Neutralization of adrenomedullin inhibits the growth of human glioblastoma cell lines in vitro and suppresses tumor xenograft growth in vivo.

Authors:  L'Houcine Ouafik; Samantha Sauze; Françoise Boudouresque; Olivier Chinot; Christine Delfino; Frédéric Fina; Vincent Vuaroqueaux; Christophe Dussert; Jacqueline Palmari; Henri Dufour; François Grisoli; Pierre Casellas; Nils Brünner; Pierre-Marie Martin
Journal:  Am J Pathol       Date:  2002-04       Impact factor: 4.307

7.  RNA interference targeting adrenomedullin induces apoptosis and reduces the growth of human bladder urothelial cell carcinoma.

Authors:  Ai-guang Liu; Xi-zhong Zhang; Fen-bao Li; Yong-li Zhao; Ying-chang Guo; Rui-min Yang
Journal:  Med Oncol       Date:  2013-05-29       Impact factor: 3.064

Review 8.  Peptide processing and biology in human disease.

Authors:  Suzana Kovac; Arthur Shulkes; Graham S Baldwin
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2009-02       Impact factor: 3.243

9.  Elevated expression of adrenomedullin is correlated with prognosis and disease severity in osteosarcoma.

Authors:  Xing Dai; Wei Ma; Xijing J He; Rajiv Kumar Jha
Journal:  Med Oncol       Date:  2012-12-27       Impact factor: 3.064

10.  The ADMR receptor mediates the effects of adrenomedullin on pancreatic cancer cells and on cells of the tumor microenvironment.

Authors:  Vijaya Ramachandran; Thiruvengadam Arumugam; Robert Langley; Rosa F Hwang; Pablo Vivas-Mejia; Anil K Sood; Gabriel Lopez-Berestein; Craig D Logsdon
Journal:  PLoS One       Date:  2009-10-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.